What question did this study set out to answer?

To review lipid-based delivery systems enabling oral amphotericin B administration and evaluate emerging strategies, including nanocochleates and lipid-drug conjugates in emulsions.

January 5, 2023Drug DeliveryOpen Access

Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application

View Full Paper

Ask AI

Bookmark

Authors

XZXiaoming Zhong JYJianqiong Yang HLHongyan Liu

Discussion

Member takes

Overview

Review highlights lipid-based delivery strategies for oral amphotericin B in invasive fungal infections, indicating viable alternatives to intravenous administration.

Key Points

To review lipid-based delivery systems enabling oral amphotericin B administration and evaluate emerging strategies, including nanocochleates and lipid-drug conjugates in emulsions.
Reviewed clinical and preclinical literature on formulation strategies developed to overcome the poor oral bioavailability of amphotericin B.
Assessed progress for oral formulations currently advancing through phase I clinical evaluation.
Identified two oral lipid-based amphotericin B formulations that have progressed into phase I clinical trials.
Highlighted amphotericin B-lipid conjugates combined with emulsions and nanocochleates as viable strategies demonstrating enhanced oral bioavailability.

Cite This Study

Zhong et al. (2023) studied this question.

synapsesocial.com/papers/6a92abf2eba2c67b4da5fba3 https://doi.org/10.1080/10717544.2022.2161671

View Full Paper

Ask AI

Bookmark

January 5, 2023Drug DeliveryOpen Access

Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application

View Full Paper

Ask AI

Bookmark

Authors

XZXiaoming Zhong JYJianqiong Yang HLHongyan Liu

Discussion

Member takes

Overview

Review highlights lipid-based delivery strategies for oral amphotericin B in invasive fungal infections, indicating viable alternatives to intravenous administration.

Key Points

To review lipid-based delivery systems enabling oral amphotericin B administration and evaluate emerging strategies, including nanocochleates and lipid-drug conjugates in emulsions.
Reviewed clinical and preclinical literature on formulation strategies developed to overcome the poor oral bioavailability of amphotericin B.
Assessed progress for oral formulations currently advancing through phase I clinical evaluation.
Identified two oral lipid-based amphotericin B formulations that have progressed into phase I clinical trials.
Highlighted amphotericin B-lipid conjugates combined with emulsions and nanocochleates as viable strategies demonstrating enhanced oral bioavailability.

Cite This Study

Zhong et al. (2023) studied this question.

synapsesocial.com/papers/6a92abf2eba2c67b4da5fba3 https://doi.org/10.1080/10717544.2022.2161671

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark